Informations

Breast cancer is the most common malignancy among women worldwide, with approximately 5% to 10% of patients carrying BRCA gene mutations. These patients often present with more advanced disease, face a higher risk of recurrence, and have poorer prognoses. For patients with germline BRCA-mutated (gBRCA) triple-negative breast cancer (TNBC), platinum-based chemotherapy remains the standard treatment…

Breast cancer is the most common malignancy among women worldwide, with approximately 5% to 10% of patients carrying BRCA gene mutations. These patients often present with more advanced disease, face a higher risk of recurrence, and have poorer prognoses. For patients with germline BRCA-mutated (gBRCA) triple-negative breast cancer (TNBC), platinum-based chemotherapy remains the standard treatment…

At the highly anticipated 2024 San Antonio Breast Cancer Symposium (SABCS), numerous groundbreaking studies in breast cancer treatment were unveiled. Among them, the Working Group for Gynecological Oncology (WSG) presented long-term survival data from the WSG ADAPT-HR+/HER2- early breast cancer chemotherapy cohort (Abstract No.: GS3-04). This study integrates clinical pathology, genomic testing, and endocrine therapy…

The 16th Shanghai Breast Cancer Symposium and Annual Meeting of the Shanghai Anti-Cancer Association Breast Cancer Committee, hosted by the Chinese Anti-Cancer Association Breast Cancer Professional Committee (CBCS) and the Shanghai Anti-Cancer Association, and organized by the Breast Cancer Professional Committee of the Shanghai Anti-Cancer Association, was held from December 20 to 21, 2024, in…

In the field of immunotherapy for colorectal cancer (CRC), ADAR1, an essential RNA-editing enzyme, has gained significant attention in recent years. At the 2024 ESMO Asia Congress, Dr. Da Kang from Dr. Zhizhong Pan’s team at the Sun Yat-sen University Cancer Center presented their latest findings on ADAR1 expression in T cells and its impact…

Previous Phase II NEOTAX study results demonstrated that neoadjuvant therapy with toripalimab combined with axitinib effectively downstaged inferior vena cava tumor thrombi in some patients with renal cell carcinoma (RCC), significantly improving perioperative outcomes. However, resistance to therapy remains a challenge for some patients, necessitating further investigation. At the 2024 ESMO ASIA Congress, Dr. Liangyou…

Epidermal growth factor receptor (EGFR) gene mutations are the most common oncogenic driver mutations in non-small cell lung cancer (NSCLC) patients in China, with a significantly higher incidence compared to Caucasian populations. At the recent ESMO Asia Congress 2024, Dr. Li Zhang from the Sun Yat-sen University Cancer Center presented results from the Phase II…